Exhibit 10.4

 

OMNIBUS AGREEMENT

 

This Omnibus Agreement (this “Agreement”) is entered into as of November 16, 2026 by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and JUPITER NEUROSCIENCES, INC., a company incorporated under the laws of the State of Delaware (the “Company”), with reference to (1) that certain Standby Equity Purchase Agreement, dated as of October 24, 2025, by and between the Investor and the Company and the amendment thereto dated November 19, 2025 (such agreement, the “SEPA”), (2) that certain Registration Rights Agreement, dated as of October 24, 2025, by and between the Investor and the Company (such agreement, the “RRA”), (3) that certain Convertible Promissory Note, issued October 24, 2025 in an original principal amount of $4,000,000 delivered by the Company to the Investor and bearing Number JUNS-1 (the “October Note”), (4) that certain Convertible Promissory Note, issued December 23, 2025 in an original principal amount of $2,000,000 delivered by the Company to the Investor and bearing Number JUNS-2 (the “December Note” and, together with the October Note, the “Notes”), and (5) that certain Omnibus Amendment dated as of February 20, 2026, by and between the Investor and the Company (such agreement, the “Omnibus”). Collectively, the SEPA, RRA, the Notes, the Omnibus and all other instruments, agreements or other items executed or delivered in connection with either of the foregoing are referred to as the “Transaction Documents.” Undefined terms herein have the same definitions set forth in the Transaction Documents. The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.”

 

By this Agreement, the Company and the Investor have agreed to the following terms:

 

1. Monthly Payments. Pursuant to the Omnibus, the Company was obligated to make monthly cash payments on the Installment Dates outlined in the Repayment Schedule attached thereto. As of the date hereof, there remains $217,938 due and outstanding on the final payment which was due on October 1, 2026 (“Outstanding Balance”). The Parties have agreed that such Outstanding Balance shall be paid to the Investor no later than December 16, 2026 (the “Payment Date”).

 

2. Extension Fee. As consideration for the extension of the October 1, 2026 Installment Date, the Company shall pay to the Investor on the Payment Date the Outstanding Balance plus an extension fee of $21,793.80 (the “Extension Fee”).

 

3. Post Effective Amendment of Registration Statement. If the Company has not paid to the Investor the Outstanding Balance and the Extension Fee as of the Payment Date, the Company shall file a post effective amendment of registration statement No. 333-297073 registering additional shares of the Company’s Common Stock to be issued pursuant to the SEPA no later than January 2, 2027 and shall pay to the Investor the Outstanding Balance and the Extension Fee no later than January 31, 2027 (the “Outside Payment Date”).

 

 

 

 

4. Effect; Continuing Validity. The SEPA, RRA, and the Notes are amended to the extent necessary to give effect to this Agreement, and the terms of this Agreement shall supersede any contrary terms in the SEPA, RRA, and the Notes. Each reference to the “Note” in the October Note and the December Note shall be deemed to refer to the Notes as modified by this Agreement. Except as specifically set forth herein, the terms and conditions of the SEPA, RRA, and the Notes shall remain unmodified and are hereby ratified by the Parties. The Company acknowledges and agrees that, except as otherwise expressly provided in this Agreement, all terms, conditions and provisions of the SEPA, RRA, and the Notes shall continue in full force and effect and remain unaffected and unchanged. This Agreement in no way acts as a release or relinquishment of, and in no way affects, the liens, security interests and rights created by or arising under the Transaction Documents, or the priority thereof. Such liens, security interests and rights are hereby ratified, confirmed, renewed and extended in all respects. The Transaction Documents, any other security for payment of the Notes, and all rights, remedies, titles, liens and equities securing the Transaction Documents as hereby modified and the indebtedness represented thereby are hereby recognized, renewed, extended and continued in full force and effect for the benefit of the Investor and the indebtedness evidenced thereby.

 

5. Not a Novation. This Agreement is a modification only and not a novation. This Agreement is to be considered attached to the Notes and made a part thereof. This Agreement shall not release or affect the liability of any guarantor, surety or endorser of the Notes, or release any owner of collateral securing the Notes. The validity, priority and enforceability of the Notes shall not be impaired hereby.

 

6. From and after the date hereof, this Agreement is and shall be deemed a part of the Notes and shall be deemed a Transaction Document. An event of default under this Agreement shall constitute an Event of Default under the Notes.

 

7. Miscellaneous. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. This Agreement may be executed in counterparts, each of which, when so executed, shall be deemed an original, but all such counterparts, taken together, shall constitute one and the same instrument. Delivery of an executed counterpart of this Amendment electronically shall be equally as effective as delivery of a manually executed counterpart of this Agreement. No waiver of any provision of this Agreement shall be effective or enforceable unless made in writing signed by the party waiving any right or privilege hereunder.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 

 

 

IN WITNESS WHEREOF, the Company and the Investor have caused this Amendment to be duly executed by a duly authorized representative as of the date first written above.

 

  COMPANY:
     
  JUPITER NEUROSCIENCES, INC.
     
  By: /s/ Christer Rosén
  Name: Christer Rosén
  Title: Chairman and Chief Executive Officer

 

 

 

 

  INVESTOR:
     
  YA II PN, Ltd.
     
  By: Yorkville Advisors Global, LP Its: Investment Manger
     
  By: Yorkville Advisors Global II, LLC Its: General Partner
     
  By: /s/ David Gonzalez
  Name: David Gonzalez
  Title: Counsel